A Phase 3 trial of the Bayer compound, regorafenib, in patients with metastatic gastrointestinal stromal tumours (GIST) has met its primary endpoint of progression-free survival, according to the sponsors. Data are being presented at Asco on 4 June.
Roche said that its antibody-drug conjugate, trastuzumab emtansine (T-DM1), has met its co-primary endpoint of a significant improvement in progression-free survival in a Phase 3 study of patients with HER2-positive metastatic breast cancer.
4SC AG said that its cancer therapy, resminostat, in combination with sorafenib, achieved a progression-free survival of 4.7 months after 12 weeks in patients with advanced liver cancer. Data will be presented at ASCO on 4 June.
Bristol-Myers Squibb Company is mobilising researchers at 10 different institutes in the US and Europe to investigate the role of immunotherapies in treating cancer. The project has been launched under the name ‘immuno-oncology network’.
GlaxoSmithKline Plc has announced the start of two Phase 3 studies that will evaluate the effectiveness of a new combination therapy for the treatment of patients with BRAF-positive metastatic cutaneous melanoma. The studies will also look at safety.
H. Lundbeck A/S said that its experimental treatment for Alzheimer’s disease, Lu AE58054, met its primary endpoint in a Phase 2 proof-of-concept study of 278 patients with moderate disease already being treated with donepezil. Full data will be disclosed at upcoming medical meetings.
Ensemble Therapeutics Corporation and Genentech (Roche) have entered into a collaboration to discover new drug candidates using the US company’s macrocyclic technology platform. Financial terms were not disclosed.
The Karolinska University Hospital and GE Healthcare Life Sciences have started a joint research collaboration to address some of the issues associated with the manufacture and development of new cell therapies. Financial terms weren’t given.
The European Commission and the pharmaceutical industry have committed €223.7 million to research new antibiotic medicines in the first of several projects to be carried under the Innovative Medicines Initiative (IMI).
A Phase 3 trial of Nexavar (sorafenib) in patients with advanced, relapsed non-small cell lung cancer has failed to meet its primary endpoint of improving overall survival, according to Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals Inc.